Treatment

KYV101 clinical trials

1 indexed studies · 0 currently recruiting

Active not recruitingPHASE1, PHASE2
Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis
This study compares a new cell therapy (KYV101) with an existing medicine (Rituximab) for severe rheumatoid arthritis that hasn't responded to other treatments. It checks how safe and effective they are at reducing disease activity and certain antibodies.
For: Rheumatoid Arthritis
Germany